dacomitinib

Overview

Dacomitinib is a second-generation irreversible pan-HER (EGFR/HER2/HER4) tyrosine kinase inhibitor. It is FDA-approved for first-line treatment of EGFR-mutant metastatic non-small cell lung cancer.

Evidence in the corpus

  • Cited as a preferred agent alongside afatinib and osimertinib for atypical EGFR alleles (L861Q, exon 18 deletions) in the 860-patient MSK-IMPACT LUAD cohort; L861Q had significantly lower clinical-benefit rates with first-generation TKIs (43% vs 87.3% overall for sensitizing EGFR; p=0.039 vs L858R), supporting clinical evaluation of second/third-generation agents including dacomitinib for these alleles PMID:28336552.

Resistance mechanisms

  • Not reported in corpus.

Cancer types (linked)

Sources

  • PMID:28336552 — MSK-IMPACT LUAD cohort (n=860); dacomitinib cited as preferred agent for atypical EGFR alleles (L861Q, exon 18 del) with lower clinical-benefit rates on first-generation TKIs.

This page was processed by crosslinker on 2026-05-14.